Table 6 Incidence of treatment-related adverse events in 78 patients with advanced hepatocellular carcinoma who underwent low-dose nivolumab
From: Low-dose nivolumab in advanced hepatocellular carcinoma
Adverse event | Any grades | Grade 3/4 |
|---|---|---|
Rash | 7 (8.9%) | 0 (0%) |
Pruritis | 5 (6.4%) | 0 (0%) |
Diarrhea | 4 (5.1%) | 0 (0%) |
Decreased appetite | 3 (3.8%) | 0 (0%) |
Fatigue | 9 (11.5%) | 0 (0%) |
Decreased body weight | 2 (2.6%) | 0 (0%) |
Aspartate/Alanine aminotransferase increase | 4 (5.1%) | 0 (0%) |
Nausea | 2 (2.6%) | 0 (0%) |
Hyperthyroidism | 1 (1.3%) | 0 (0%) |
Hypothyroidism | 2 (2.6%) | 0 (0%) |
Pneumonitis | 0 (0%) | 0 (0%) |
Hypersensitivity/infusion-related reaction | 2 (2.6%) | 0 (0%) |